In December 2017, Peste des Petits Ruminants (PPR) emerged in Burundi (East Africa) and rapidly spread to five provinces (Gitega, Kirundo, Mwaro, Muramvya and Karuzi) in the country, causing severe disease and killing more than 4,000 goats in the province of Gitega alone. An initial outbreak investigation was conducted in December 2017 by the Burundi Government Veterinary Services and samples were collected for laboratory confirmation. A competitive Enzyme Linked Immuno-Sorbent Assay (cELISA: Chinese Patent No. ZL201210278970.9) supplied by the Lanzhou Veterinary Research Institute was used to test 112 sera and results showed around 37.5% positive samples. This high level of PPR positive sera in an animal population where PPR infection and vaccination had not been previously reported indicated the exposure of the animals to PPRV. Subsequently in January 2018, the laboratory tests conducted at the African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC) laboratories following a joint investigative mission by the African Union-Interafrican Bureau for Animal Resources (AU-IBAR), AU-PANVAC and the East African Community (EAC) confirmed the presence of PPR in Burundi. Samples tested by conventional RT-PCR indicated the presence of the PPR virus (PPRV). Confirmatory isolation of the virus was also performed. Phylogenetic analysis revealed that the virus belongs to lineage III and shows a close relationship with PPRV isolates from Kenya in 2011 and Uganda in 2012. A possible explanation for the outbreaks of PPR in Burundi between December 2017 and February 2018 is presented.

Peste des petits ruminants virus (PPRV), which is the only member of the Morbillivirus caprinae species and belongs to the genus Morbillivirus within the Paramyxoviridae family, causes the highly contagious viral sickness “Peste des petits ruminants (PPR).” PPR is of serious economic significance for small ruminant production, particularly in Africa. Control of this critical disease depends highly on successful vaccination against the PPRV. An in-depth understanding of the genetic evolution of the live-attenuated PPR vaccine Nigeria 75/1 strain used in Africa is essential for the successful eradication of this disease by 2030. Therefore, this study investigated the possible genetic evolution of the PPR vaccine produced by various African laboratories compared with the master seed available at AU-PANVAC. RT-PCR was performed to amplify a segment of the hypervariable C-terminal part of the nucleoprotein (N) from commercial batches of PPR vaccine Nigeria 75/1 strain. The sequences were analyzed, and 100% nucleotide sequence identity was observed between the master seed and vaccines produced. The results of this study indicate the genetic stability of the PPR vaccine from the Nigeria 75/1 strain over decades and that the vaccine production process used by different manufacturers did not contribute to the emergence of mutations in the vaccine strain.

Enzyme linked immunosorbent assays (ELISAs) have been developed for the detection of antibodies against contagious caprine pleuropneumonia (CCPP), the causative agent of which is Mycoplasma capricolum subsp. Capripneumoniae (Mccp). The currently available commercial CCPP competitive ELISA (CCPP cELISA) kit produced and supplied by IDEXX Company (Westbrook, Maine, United States) is relatively expensive for most African laboratories. To address this issue and provide a variety of choices, a sensitive and specific blocking-ELISA (b-ELISA) test to detect antibodies against CCPP was developed. We describe the newly developed CCPP blocking-ELISA based on the blocking of an epitope of a monoclonal antibody (Mccp-25) by a positive serum sample against the Mccp protein coated on a plate. The Percentage Inhibition (PI) cut-off value for the CCPP b-ELISA was set at 50 using 466 CCPP negative and 84 CCPP positive small ruminant sera. Of the negative sera, 307 were obtained from the Botswana National Veterinary Laboratory (BNVL) and 159 from the Friedrich-Loeffler-Institute (FLI) Germany. The 84 positive sera samples came from experimentally vaccinated goats at the AU-PANVAC facility in Debre-Zeit, Ethiopia. The relative diagnostic sensitivity and specificity of the CCPP b-ELISA was 93% and 88%, respectively. This test result indicated good correlation with that of the commercial CCPP cELISA by IDEXX Company (Westbrook, Maine, United States) with a Cohen’s κ agreement of κ agreement of 0.85. The newly developed CCPP b-ELISA will be useful in the detection of antibodies for the diagnosis CCPP and for sero-surveillance during vaccination campaigns.